A major hurdle in EV-based therapies is the "yield gap" — standard lab protocols simply cannot produce the volume of extracellular vesicles (EVs) required for clinical applications. However, scale-up could impact the quality and potency of therapeutic EVs. In our latest co-authored study published in 𝗦𝘁𝗲𝗺 𝗖𝗲𝗹𝗹𝘀 𝗧𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲, the teams at Exosomica, the Innovative Medicine Centre, the University of Latvia, alongside TAmiRNA scientists, addressed this challenge head-on. Together, we applied deep molecular fingerprinting and in vivo potency studies to validate a new large-scale production protocol for Parkinson’s Disease (PD) therapies. By leveraging our specialized transcriptomic and proteomic pipelines, we analyzed how production and purification methods shape the EV "message": ✅ 𝟯𝗗 𝘃𝘀. 𝟮𝗗 𝗖𝗼𝗺𝗽𝗮𝗿𝗶𝘀𝗼𝗻: Our analysis [...]